For millions of men seeking to sluggish or reverse hair loss, finasteride has been a widely prescribed solution for over two decades. But a growing body of evidence suggests a darker side to this popular drug, linking it to an increased risk of depression, anxiety, and, tragically, suicide. A new analysis by Prof. Mayer Brezis of the Hebrew University of Jerusalem underscores these concerns, arguing that regulators and the pharmaceutical industry have repeatedly overlooked warning signs, potentially at a significant cost to public health.
Brezis’s review, published recently, analyzed data from eight large studies conducted between 2017 and 2023, alongside adverse event reports and health records from countries including Sweden, Canada, and Israel. The findings consistently demonstrate a higher incidence of mood disorders and suicidal thoughts among individuals using finasteride compared to those who did not. This pattern, he contends, is no longer anecdotal but a clear and concerning trend.
The core of the issue, according to Brezis, isn’t simply the existence of these side effects, but the delayed and inadequate response from both the Food and Drug Administration (FDA) and Merck, the drug’s manufacturer. While the FDA acknowledged depression as a potential side effect in 2011 and added suicidal thoughts to the drug label in 2022, researchers had been raising alarms about potential psychiatric dangers as early as 2002. Internal FDA documents from 2010, cited in the review, reveal redacted sections containing estimates of the potential impact on users – information that wasn’t fully acted upon.
A History of Underreporting and Delayed Action
The scale of the potential problem is alarming. By 2011, only 18 suicides linked to finasteride had been reported to the FDA. However, Brezis estimates, based on worldwide usage figures, that the actual number should have been in the thousands. He attributes this discrepancy not merely to underreporting, but to a “systemic failure of pharmacovigilance” – the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.
This failure, Brezis argues, is partly attributable to finasteride’s classification as a cosmetic treatment rather than a drug addressing a life-threatening condition. Unlike medications for obesity or psychiatric disorders, which are subject to more rigorous post-approval monitoring, finasteride received comparatively less scrutiny. Crucially, none of the data-mining studies referenced in the review were initiated by Merck or commissioned by regulatory authorities. The FDA’s MedWatch program relies heavily on voluntary reporting, which can be incomplete.
The Biological Link and “Post-Finasteride Syndrome”
Finasteride works by blocking the enzyme that converts testosterone into dihydrotestosterone (DHT), a hormone linked to hair loss. However, this process can also disrupt the production of neurosteroids, such as allopregnanolone, which play a crucial role in mood regulation. Animal studies have demonstrated that long-term finasteride use can lead to neuroinflammation and even structural changes in the hippocampus, a brain region involved in emotional processing.
For some patients, the consequences extend beyond the duration of treatment. A constellation of lingering symptoms, often referred to as “post-finasteride syndrome,” can include insomnia, panic attacks, cognitive dysfunction, and persistent suicidal thoughts – even years after discontinuing the drug. While the existence and prevalence of this syndrome are still debated within the medical community, patient advocacy groups and increasing research suggest it’s a real and debilitating condition.
Regulatory Reform and Corporate Responsibility
Brezis’s report is sharply critical of both the FDA and Merck. He argues that despite possessing the tools and data to identify and address the risks associated with finasteride, neither entity acted decisively. He suggests that the industry’s silence may have been driven by market pressures and concerns about legal liability – a pattern reminiscent of controversies surrounding Merck’s handling of the painkiller Vioxx.
Organon, which now markets finasteride following a spin-off from Merck, stated, “Nothing is more essential to Organon than the safety of our medicines.” However, the company has not initiated the independent safety studies called for by critics. Organon’s website provides information about their commitment to patient safety.
The FDA, meanwhile, took five years to respond to a citizen petition requesting a “black box warning” – the most stringent type of warning on prescription drugs. Their eventual decision was to add suicidal ideation to the label, but not as a formal black box warning.
Brezis is advocating for significant changes in how drugs like finasteride are approved, monitored, and prescribed. His recommendations include suspending the marketing of the drug for cosmetic purposes until its safety can be re-established, mandating post-approval studies with strict enforcement mechanisms, and systematically recording drug histories in suicide investigations. He also emphasizes the need for greater transparency and accountability from both pharmaceutical companies and regulatory agencies.
“For many, those changes come too late,” Brezis writes, dedicating his paper to a previously healthy man who, after starting finasteride for hair loss, rapidly descended into severe psychiatric distress and ultimately took his own life. This tragic case underscores the urgent need for a more proactive and protective approach to drug safety.
The debate surrounding finasteride highlights a broader issue within the pharmaceutical industry: the balance between cosmetic enhancements and potential health risks. As research continues to emerge, and as patient experiences are shared, a more comprehensive understanding of the drug’s long-term effects is crucial for informed decision-making and responsible healthcare.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment. If you are experiencing suicidal thoughts or a mental health crisis, please reach out for help. You can contact the 988 Suicide & Crisis Lifeline by calling or texting 988 in the US and Canada, or by dialing 111 in the UK.
The FDA is expected to review new data on finasteride’s potential psychiatric side effects at its next advisory committee meeting in early 2025. Further updates and information can be found on the FDA website. Share your thoughts and experiences in the comments below.
